Drug Trial Radar · NCT07235384
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Dec 28, 2027
Study completion Dec 28, 2027
Sponsor
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)
Conditions
- Atopic Dermatitis (AD)
Interventions
ZL-1503Drug
Healthy volunteers will receive ZL-1503.
PlaceboDrug
Healthy volunteers will receive placebo.
ZL-1503Drug
Participants with moderate to severe atopic dermatitis will receive ZL-1503.
PlaceboDrug
Participants with moderate to severe atopic dermatitis will receive placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to 48 weeks after last intervention
- Number of participants with serious adverse events (SAEs)Time frame: Up to 48 weeks after last intervention
- Number of participants with clinical laboratory abnormalitiesTime frame: Up to 48 weeks after last intervention
- Number of participants with vital sign abnormalitiesTime frame: Up to 48 weeks after last intervention
- Number of participants with electrocardiogram (ECG) abnormalitiesTime frame: Up to 48 weeks after last intervention
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
Veracity Clinical Research
Woolloongabba, Queensland, Australia · Recruiting
Skin Health Institute
Carlton, Victoria, Australia · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
Dermatology Hospital of Jiangxi Province
Nanchang, Jiangxi, China · Recruiting
Shandong Provincial Dermatology Hospital
Jinan, Shandong, China · Recruiting
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China · Recruiting
Aotearoa Clinical Trials
Auckland, Auckland, New Zealand · Recruiting
Momentum Auckland
Takapuna, Auckland, New Zealand · Recruiting
Momentum Hamilton
Hamilton, Hamilton, New Zealand · Recruiting
Momentum Palmerston North
Palmerston North, Mananwatu, New Zealand · Recruiting
Momentum Hutt Valley
Upper Hutt, Wellington Region, New Zealand · Recruiting
Momentum Kapiti
Waikanae, Wellington Region, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.